Legend Biotech (NASDAQ:LEGN) CEO Ingrid Zhang Buys 20,000 Shares of Stock

Legend Biotech logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CEO Ingrid Zhang bought 20,000 shares for $163,200 at an average price of $8.16, increasing her direct holdings by 1.77% to 1,151,860 shares.
  • Legend Biotech reported quarterly EPS of $0.14, beating the $0.01 consensus, while revenue of $359.5 million came in slightly below expectations and rose 32% year over year.
  • Analysts collectively rate the stock a Moderate Buy, with an average price target of $48.64; shares recently traded at $15.25, near their one-year low of $15.15.
  • Five stocks to consider instead of Legend Biotech.

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Get Free Report) CEO Ingrid Zhang purchased 20,000 shares of the stock in a transaction on Tuesday, November 17th. The shares were acquired at an average price of $8.16 per share, for a total transaction of $163,200.00. Following the transaction, the chief executive officer directly owned 1,151,860 shares of the company's stock, valued at $9,399,177.60. This represents a 1.77% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Legend Biotech Stock Performance

Shares of NASDAQ:LEGN traded down $0.85 during midday trading on Friday, reaching $15.25. 3,419,205 shares of the company's stock traded hands, compared to its average volume of 2,439,548. The company has a market cap of $2.96 billion, a P/E ratio of -1,523.48 and a beta of 0.55. The company has a fifty day simple moving average of $19.24 and a two-hundred day simple moving average of $22.09. Legend Biotech Corporation Sponsored ADR has a 1 year low of $15.15 and a 1 year high of $37.50.

Legend Biotech (NASDAQ:LEGN - Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.13. The business had revenue of $359.50 million during the quarter, compared to analysts' expectations of $361.46 million. Legend Biotech had a negative net margin of 0.02% and a negative return on equity of 0.03%. The company's quarterly revenue was up 32.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.05) earnings per share. As a group, research analysts forecast that Legend Biotech Corporation Sponsored ADR will post -0.02 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of LEGN. American Century Companies Inc. acquired a new position in Legend Biotech in the third quarter valued at approximately $925,000. Aquatic Capital Management LLC acquired a new stake in Legend Biotech during the third quarter worth $1,399,000. Lighthouse Investment Partners LLC purchased a new stake in Legend Biotech in the third quarter valued at $770,000. Ieq Capital LLC purchased a new stake in Legend Biotech in the third quarter valued at $937,000. Finally, Public Sector Pension Investment Board raised its position in Legend Biotech by 3.9% in the third quarter. Public Sector Pension Investment Board now owns 26,789 shares of the company's stock valued at $533,000 after purchasing an additional 1,000 shares during the period. Institutional investors and hedge funds own 70.89% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on LEGN shares. Weiss Ratings raised Legend Biotech from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, November 9th. UBS Group restated a "buy" rating and issued a $65.00 price objective on shares of Legend Biotech in a report on Monday, September 28th. Raymond James Financial restated an "outperform" rating and issued a $58.00 price objective on shares of Legend Biotech in a report on Monday, July 27th. HC Wainwright reaffirmed a "buy" rating on shares of Legend Biotech in a report on Friday, October 30th. Finally, Barclays dropped their target price on shares of Legend Biotech from $68.00 to $61.00 and set an "overweight" rating for the company in a report on Wednesday, November 11th. Nine equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $48.64.

Get Our Latest Stock Report on LEGN

Key Stories Impacting Legend Biotech

These are some of the LEGN stories that stood out recently:

  • Positive Sentiment: HC Wainwright maintained its Buy rating and forecasts Legend Biotech will earn $0.24 per share in FY2026, followed by $1.18 per share in FY2027. A separate report cites a brokerage consensus price target of $50.85. Brokerage consensus price target report
  • Neutral Sentiment: A recent article asks whether a return to profitability changes the investment case, but the available report details do not specify its conclusions. Yahoo Finance article on Legend Biotech’s return to profit
  • Negative Sentiment: HC Wainwright cut its EPS estimates across several upcoming periods: FY2027 to $1.18 from $1.70, Q1 2027 to $0.14 from $0.26, and Q2 2027 to $0.22 from $0.36. It also reduced its Q3 and Q4 2027 forecasts. The broad revisions signal a less favorable earnings outlook and could pressure the shares, although the firm kept its Buy rating. Legend Biotech stock and analyst information

About Legend Biotech

(Get Free Report)

Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson's Innovative Medicine business, which collaborates on its commercialization.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Legend Biotech Right Now?

Before you consider Legend Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Legend Biotech wasn't on the list.

While Legend Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines